PBLS (Parabilis Medicines) Net Change in Cash: $-19.57 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PBLS Parabilis Medicines Inc PBLS
10 GF Score
Price $38.85
! 2 Warning Signs
View Full Analysis

What is Parabilis Medicines Net Change in Cash?

Parabilis Medicines PBLS -2.71% 10 Net Change in Cash is $-19.57 Mil as of Dec. 2025. GuruFocus rates PBLS with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Parabilis Medicines's Net Change in Cash for the six months ended in Dec. 2025 was $-19.57 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2025 was $-19.57 Mil.

Parabilis Medicines Net Change in Cash Historical Data

* Premium members only.

The historical data trend for Parabilis Medicines's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Parabilis Medicines Net Change in Cash Chart

Parabilis Medicines Annual Data
Trend Dec24 Dec25
Net Change in Cash
4.70 -19.57

Parabilis Medicines Semi-Annual Data
Dec24 Dec25
Net Change in Cash 4.70 -19.57
PBLS
10GF Score
Parabilis Medicines Inc PBLS
Net Change in Cash is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Parabilis Medicines Net Change in Cash Calculation

Parabilis Medicines's Net Change in Cash for the fiscal year that ended in Dec. 2025 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-123.713+39.758+64.382+0
=-19.57

Parabilis Medicines's Net Change in Cash for the quarter that ended in Dec. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-123.713+39.758+64.382+0
=-19.57

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2025 was $-19.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Change in Cash →
What does a Net Change in Cash of $-19.57 Mil mean?
Parabilis Medicines (PBLS) has a Net Change in Cash of $-19.57 Mil as of Dec. 2025. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Parabilis Medicines and its competitors.
Is Parabilis Medicines' Net Change in Cash too high?
Parabilis Medicines' current Net Change in Cash is $-19.57 Mil. Overall, Parabilis Medicines has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Parabilis Medicines' Net Change in Cash compare to DYN and ACAD?
Parabilis Medicines' Net Change in Cash of $-19.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Change in Cash for a Biotechnology company?
A good Net Change in Cash depends on the Biotechnology industry context. However, Net Change in Cash should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Change in Cash mean?
A high Net Change in Cash can signal that a stock is expensive relative to its fundamentals. The net change in cash is the total change in cash and equivalents between the current period and the past period. View historical data for Parabilis Medicines and its competitors. Parabilis Medicines's current Net Change in Cash is $-19.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parabilis Medicines stock overvalued right now?
Parabilis Medicines (PBLS) has a current Net Change in Cash of $-19.57 Mil. The current Net Change in Cash is $-19.57 Mil. Parabilis Medicines' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Change in Cash calculated?
Net Change in Cash is calculated from a company's financial statements. For Parabilis Medicines (PBLS), the current Net Change in Cash is $-19.57 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Parabilis Medicines Business Description

Address 30 Acorn Park Drive, Cambridge Discovery Park, Cambridge, MA, USA, 02140
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between ?-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/?-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.
10GF Score

Get the complete analysis for PBLS

Net Change in Cash is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$38.85
Price